{"id":968790,"date":"2026-05-30T08:04:40","date_gmt":"2026-05-30T12:04:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enzamet-trial-shows-veracytes-decipher-prostate-test-identifies-which-patients-benefit-from-adding-chemotherapy-in-metastatic-prostate-cancer\/"},"modified":"2026-05-30T08:04:40","modified_gmt":"2026-05-30T12:04:40","slug":"enzamet-trial-shows-veracytes-decipher-prostate-test-identifies-which-patients-benefit-from-adding-chemotherapy-in-metastatic-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enzamet-trial-shows-veracytes-decipher-prostate-test-identifies-which-patients-benefit-from-adding-chemotherapy-in-metastatic-prostate-cancer\/","title":{"rendered":"ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer"},"content":{"rendered":"

<\/p>\n

ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer<\/b><\/p>\n

Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease<\/i><\/p>\n

Additional ASCO data reinforce Decipher Prostate\u2019s utility in high-risk localized disease<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc.<\/a> (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial<\/a> presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1<\/sup> evidence for a genomic test guiding this decision. Complementary data presented at the meeting also reinforce Decipher Prostate’s clinical utility in high-risk localized disease.<\/p>\n

\nApproximately 334,000 men are diagnosed with prostate cancer annually in the United States, including about 30,000 who present with metastatic disease at diagnosis.2, 3 <\/sup>While recent treatment advances have improved outcomes, clinicians still lack precision tools to guide chemotherapy decisions in this setting.<\/p>\n

\n\u201cFor the first time, the ENZAMET trial analysis shows that a genomic test can guide the decision to add chemotherapy to standard of care hormonal therapy in metastatic prostate cancer,” said Prof. Christopher Sweeney, M.B.B.S., DHS., Lead Investigator, South Australian Immunogenomics Cancer Institute, Adelaide University. “Decipher Prostate identifies which patients benefit from treatment intensification, and which can be safely spared chemotherapy, giving clinicians an actionable, evidence-based answer.\u201d<\/p>\n

\nThe ENZAMET findings build on prior validation in the STAMPEDE<\/a> and CHAARTED<\/a> trials, where Decipher Prostate identified patients most likely to benefit from adding docetaxel to ADT alone. ENZAMET advances that evidence with the first demonstration that the test predicts chemotherapy benefit when added to doublet therapy (ADT plus an ARPI).<\/p>\n

Metastatic Disease: Identifying Which Men Benefit from Chemotherapy<\/b><\/p>\n

\nThe ENZAMET trial<\/a> is an international, randomized Phase III study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Researchers performed a pre-specified biomarker analysis using the Decipher Prostate test in 634 patients to assess whether the test could predict benefit from adding chemotherapy to standard hormonal therapy with a median follow-up of 5.6 years.<\/p>\n

\nResults showed:<\/p>\n